Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Smoldering MM updates: early treatment

Mohamad Mohty • 7 Dec 2019
ASH 2019
Multiple Myeloma Rare Diseases Smoldering Myeloma Dexamethasone Lenalidomide
GEM-CESAR

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, highlights the key updates in smoldering multiple myeloma (MM) from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Mohamad Mohty

5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:24
Comparing alloSCT outcomes in secondary and de-novo acute lymphoblastic leukemia
Mohamad Mohty • 15 Feb 2024
4:17
The evolving role of autoSCT in the age of CAR-T for multiple myeloma: current & future perspectives
Mohamad Mohty • 15 Feb 2024
4:02
Moving CAR-T therapy into earlier lines of treatment for myeloma and the need for effective bridging
Mohamad Mohty • 15 Feb 2024

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals